A detailed history of Pathstone Holdings, LLC transactions in Incyte Corp stock. As of the latest transaction made, Pathstone Holdings, LLC holds 10,549 shares of INCY stock, worth $760,688. This represents 0.0% of its overall portfolio holdings.

Number of Shares
10,549
Previous 9,507 10.96%
Holding current value
$760,688
Previous $628,000 15.92%
% of portfolio
0.0%
Previous 0.0%

Shares

5 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2024

Feb 14, 2025

BUY
$65.08 - $83.38 $67,813 - $86,881
1,042 Added 10.96%
10,549 $728,000
Q3 2024

Nov 07, 2024

BUY
$57.33 - $68.61 $9,516 - $11,389
166 Added 1.78%
9,507 $628,000
Q2 2024

Aug 14, 2024

BUY
$51.18 - $63.75 $128,768 - $160,395
2,516 Added 36.86%
9,341 $566,000
Q1 2024

May 13, 2024

BUY
$56.55 - $66.59 $64,297 - $75,712
1,137 Added 19.99%
6,825 $388,000
Q4 2023

Feb 14, 2024

BUY
$52.16 - $64.19 $296,686 - $365,112
5,688 New
5,688 $357,000

Others Institutions Holding INCY

About INCYTE CORP


  • Ticker INCY
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 222,431,008
  • Market Cap $16B
  • Description
  • Incyte Corporation, a biopharmaceutical company, focuses on the discovery, development, and commercialization of proprietary therapeutics in the United States and internationally. The company offers JAKAFI, a drug for the treatment of myelofibrosis and polycythemia vera; PEMAZYRE, a fibroblast growth factor receptor kinase inhibitor that act as ...
More about INCY
Track This Portfolio

Track Pathstone Holdings, LLC Portfolio

Follow Pathstone Holdings, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Pathstone Holdings, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Pathstone Holdings, LLC with notifications on news.